Követés
piero pollesello
piero pollesello
Orion Pharma
E-mail megerősítve itt: orionpharma.com
Cím
Hivatkozott rá
Hivatkozott rá
Év
Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis
R Longo, P Pollesello, C Ricci, F Masutti, BJ Kvam, L Bercich, LS Croce, ...
Journal of Magnetic Resonance Imaging 5 (3), 281-285, 1995
4831995
Noninvasive in vivo quantitative assessment of fat content in human liver
C Ricci, R Longo, E Gioulis, M Bosco, P Pollesello, F Masutti, LS Crocè, ...
Journal of hepatology 27 (1), 108-113, 1997
3961997
Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan
Z Papp, I Édes, S Fruhwald, SG De Hert, M Salmenperä, H Leppikangas, ...
International journal of cardiology 159 (2), 82-87, 2012
3732012
Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study.
P Pollesello, M Ovaska, J Kaivola, C Tilgmann, K Lundström, N Kalkkinen, ...
Journal of Biological Chemistry 269 (46), 28584-28590, 1994
3051994
Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure …
RA de Boer, G De Keulenaer, J Bauersachs, D Brutsaert, JG Cleland, ...
European journal of heart failure 21 (3), 272-285, 2019
2442019
Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels
P Kaheinen, P Pollesello, J Levijoki, H Haikala
Journal of cardiovascular pharmacology 37 (4), 367-374, 2001
2372001
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure …
C Maack, M Lehrke, J Backs, FR Heinzel, JS Hulot, N Marx, WJ Paulus, ...
European heart journal 39 (48), 4243-4254, 2018
2362018
Levosimendan: current data, clinical use and future development
MS Nieminen, S Fruhwald, LMA Heunks, PK Suominen, AC Gordon, ...
Heart, lung and vessels 5 (4), 227, 2013
2142013
The patient perspective: quality of life in advanced heart failure with frequent hospitalisations
MS Nieminen, K Dickstein, C Fonseca, JM Serrano, J Parissis, F Fedele, ...
International journal of cardiology 191, 256-264, 2015
1952015
Binding of levosimendan, a calcium sensitizer, to cardiac troponin C
T Sorsa, S Heikkinen, MB Abbott, E Abusamhadneh, T Laakso, ...
Journal of biological chemistry 276 (12), 9337-9343, 2001
1862001
Pharmacological mechanisms contributing to the clinical efficacy of levosimendan
Z Papp, K Csapó, P Pollesello, H Haikala, I Édes
Cardiovascular drug reviews 23 (1), 71-98, 2005
1842005
Biochemical and immunohistochemical evidence that in cartilage an alkaline phosphatase is a Ca2+-binding glycoprotein.
B de Bernard, P Bianco, E Bonucci, M Costantini, GC Lunazzi, ...
The Journal of cell biology 103 (4), 1615-1623, 1986
1841986
Levosimendan is a mitochondrial KATP channel opener
DM Kopustinskiene, P Pollesello, NEL Saris
European journal of pharmacology 428 (3), 311-314, 2001
1832001
The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig
S Szilágyi, P Pollesello, J Levijoki, P Kaheinen, H Haikala, I Édes, Z Papp
European journal of pharmacology 486 (1), 67-74, 2004
1662004
A role for the RISK pathway and KATP channels in pre‐ and post‐conditioning induced by levosimendan in the isolated guinea pig heart
EF Du Toit, A Genis, LH Opie, P Pollesello, A Lochner
British journal of pharmacology 154 (1), 41-50, 2008
1622008
Potassium-specific effects of levosimendan on heart mitochondria
DM Kopustinskiene, P Pollesello, NEL Saris
Biochemical pharmacology 68 (5), 807-812, 2004
1582004
The cardioprotective effects of levosimendan: preclinical and clinical evidence
P Pollesello, Z Papp
Journal of cardiovascular pharmacology 50 (3), 257-263, 2007
1522007
Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion
W Toller, M Heringlake, F Guarracino, L Algotsson, J Alvarez, ...
International Journal of Cardiology 184, 323-336, 2015
1402015
Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper
D Farmakis, J Alvarez, TB Gal, D Brito, F Fedele, C Fonseca, AC Gordon, ...
International Journal of Cardiology 222, 303-312, 2016
1392016
The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c
T Sorsa, P Pollesello, RJ Solaro
Molecular and cellular biochemistry 266, 87-107, 2004
1392004
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20